- Why Glasgow
- Help & Support
- Media Hub
- Contact Us
BioClavis has announced the planned creation of 43 new jobs with a £10.5 million investment supported by Scottish Enterprise.
Bioclavis is a new spin-out from Californian molecular profiling company Biospyder, to be based at the Clinical Innovation Zone at Glasgow’s Queen Elizabeth University Hospital, creating 43 new jobs.
BioSpyder’s investment has been supported by a £4.5m Seek & Solve research and development grant from Scottish Enterprise. It forms part of a total investment of £10.5m, which will see BioClavis adapt BioSpyder’s TempO-Seq platform technology into a novel diagnostic tool for precision medicine in a number of high value clinical indications, in close collaboration with the health service and university researchers.
Joel McComb, CEO of BioSpyder and BioClavis said: “We’re very excited to build on the success we’ve had in other molecular profiling applications and bring this novel method to bear on discovery and deployment of next generation genomic diagnostics.
“We determined Glasgow, Scotland to be the ideal location for this initiative based in large part on the support and close working relationships with Scottish Enterprise, NHS and the University.”
ScottishPower, along with Glasgow City Council, today revealed a bold new vision to transform Glasgow into the UK’s first...Read More
Kelvin Properties, the Glasgow private property company, has appointed Tay Letting to market the city’s first build-to-rent (BTR) housing...Read More
Glasgow City Council has approved the preparation of a revised business case to reconfigure the Tax Incremental Finance (TIF)...Read More
Sign-up to our email updates for the latest investment opportunities and information in Glasgow. Fill out the form below with your email.